Cargando…
Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
PURPOSE: Immunotherapy using immune checkpoint inhibitors (ICI) has revolutionized cancer treatment in recent years, particularly in melanoma. While response to immunotherapy is associated with high tumor mutational burden (TMB), PD-L1 expression, and microsatellite instability in several cancers, t...
Autores principales: | Freiberger, Sandra N., Holzmann, David, Morand, Grégoire B., Hüllner, Martin, Levesque, Mitchell P., Dummer, Reinhard, Koelzer, Viktor H., Rupp, Niels J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356647/ https://www.ncbi.nlm.nih.gov/pubmed/36527482 http://dx.doi.org/10.1007/s00432-022-04514-z |
Ejemplares similares
-
Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022) -
Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023) -
Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
por: Matković, Božica, et al.
Publicado: (2011) -
Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018) -
Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2021)